# ICTAN (NCT01996098)

> Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01996098
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Sun Yat-sen University
- Conditions: Lung Cancer
- Interventions: 6-month Icotinib; 12-month icotinib
- Enrollment: 251
- Primary outcome: Disease-Free Survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ictan-nct01996098

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01996098", "email": "<work email>"}; the inbox owner confirms by the emailed link.